咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Engineered nucleus-free mesenc... 收藏

Engineered nucleus-free mesenchymal stem cells (MSCs) for the targeted delivery of therapeutics to disease site

作     者:Zander Schwartz Piao Zhao Annie Wang Guozhi Zhao Wei Zeng Yonghui Wang Hue H. Luu Rex C. Haydon Tong-Chuan He Russell R. Reid Jason Strelzow Zander Schwartz;Piao Zhao;Annie Wang;Guozhi Zhao;Wei Zeng;Yonghui Wang;Hue H.Luu;Rex C.Haydon;Tong-Chuan He;Russell R.Reid;Jason Strelzow

作者机构:School of Biomedical EngineeringVanderbilt UniversityNashvilleTN 37235USA Molecular Oncology LaboratoryDepartment of Orthopedic Surgery and Rehabilitation MedicineThe University of Chicago Medical CenterChicagoIL 60637USA Departments of Orthopaedic Surgery and UrologyThe First Affiliated Hospital of Chongqing Medical UniversityChongqing 400016China Department of Clinical Laboratory MedicineShanghai Jiaotong University School of MedicineShanghai 200000China Laboratory of Craniofacial Suture Biology and DevelopmentDepartment of Surgery Section of Plastic SurgeryThe University of Chicago Medical CenterChicagoIL 60637USA 

出 版 物:《Genes & Diseases》 (基因与疾病(英文))

年 卷 期:2023年第10卷第2期

页      面:310-312,I0001页

核心收录:

学科分类:0710[理学-生物学] 1001[医学-基础医学(可授医学、理学学位)] 100101[医学-人体解剖与组织胚胎学] 10[医学] 

基  金:supported in part by research grants from the National Institutes of Health(No.CA226303 to TCH and No.DE030480 to RRR) supported in part by The University of Chicago Cancer Center Support Grant(No.P30CA014599) the National Center for Advancing Translational Sciences(NCATS)of the National Institutes of Health(No.5UL1TR002389) TCH was also supported by the Mabel Green Myers Research Endowment Fund and The University of Chicago Orthopaedics Alumni Fund.Funding sources were not involved in the study design 

主  题:targeted delivery sought 

摘      要:Specialized therapeutic delivery, or use of pharmaceuticals and other biomaterials to target specific parts of the body or diseased tissue, has long been sought as an ideal way of treating human diseases. A recent article published in Nature Biomedical Engineering revealed an innovative strategy to engineer nucleus-free human mesenchymal stem cells (MSCs) for targeted delivery of therapeutics to disease site.1 MSCs have emerged as promising vehicles of therapeutic delivery.2,3 MSCs are undifferentiated pluripotent stem cells derived from areas such as bone marrow and adipose tissue.4,5 MSCs are sought after for their chemotaxis, or ability to home towards a chemical stimulus, and capacity for modification with elements such as chemoattractant receptors and adhesion molecules.1 These properties allow for site-specific and minimally-invasive therapeutic administration and treatment.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分